Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non Operating Income (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Other Non Operating Income for 11 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 351.58% to -$2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.0 million through Dec 2025, down 431.68% year-over-year, with the annual reading at -$2.0 million for FY2025, 431.68% down from the prior year.
  • Other Non Operating Income for Q4 2025 was -$2.0 million at Cartesian Therapeutics, down from -$5000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $508000.0 in Q1 2024, with the low at -$2.0 million in Q4 2025.
  • Average Other Non Operating Income over 5 years is -$80647.1, with a median of $23000.0 recorded in 2023.
  • Peak annual rise in Other Non Operating Income hit 25200.0% in 2023, while the deepest fall reached 508.57% in 2023.
  • Over 5 years, Other Non Operating Income stood at $500000.0 in 2021, then plummeted by 65.0% to $175000.0 in 2022, then plummeted by 508.57% to -$715000.0 in 2023, then skyrocketed by 37.9% to -$444000.0 in 2024, then tumbled by 351.58% to -$2.0 million in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$2.0 million, -$5000.0, and -$444000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.